India News | Reported by Vishnu Som, Edited by Harish Pullanoor | Tuesday December 22, 2020
India's first and only phase III trial of a COVID-19 vaccine has crossed 13,000 subjects - the half-way mark - and proceeding successfully across multiple sites in India, Bharat Biotech, the maker of the inoculant Covaxin, announced today. The trials in the first and second phases had led to promising results.
www.ndtv.com